CDC votes for continued use of FluMist Quadrivalent vaccine in USA

22 February 2018
vaccinebig

The Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use FluMist Quadrivalent (influenza vaccine live, intranasal) in the US for the 2018-2019 season, says Anglo-Swedish pharma major AstraZeneca (LSE: AZN).

The vote is a reversal of a decision in 2016, when agency advised doctors not to use the nasal spray citing data that demonstrated it was not effective at preventing influenza. It also comes at a time that the USA is facing the most severe flu season in decades. Last year FluMist generated sales of just $78 million for AstraZeneca, with no revenues in the USA.

The recommendation follows the presentation of positive results from a US study in children between the ages of 2 to <4 years evaluating the shedding and antibody responses of the H1N1 strain in the live attenuated influenza vaccine (LAIV)/ FluMist Quadrivalent.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical